http://www.beyond-rheumatology.org/index.php/br/issue/feed Beyond Rheumatology 2019-09-04T12:14:11+02:00 Paola Granata paola.granata@pagepress.org Open Journal Systems <p><strong>Beyond Rheumatology </strong>is the new official Journal of CReI (Collegio dei Reumatologi Italiani), a scientific society that brings together outpatient care centers and hospitals rheumatologists. The aim of the Journal is to build a platform for high-quality scientific exchange between the different experts in the real life. It will be focused on publishing new discoveries on diagnostic, prognostic, clinical and therapeutic topics about rheumatology and allied conditions.</p> <p><strong>Beyond Rheumatology</strong> is an international, open access, peer-reviewed journal committed to publishing new discoveries on diagnostic, prognostic, clinical and therapeutic topics about rheumatism and allied conditions. <strong>Beyond Rheumatology</strong> aims to build a platform for high-quality scientific exchange between the different specialists largely focused on the real life of patient’s care. The Journal welcomes research works on rheumatic diseases and allied conditions, reporting perspectives and highlighting new directions also addressed to physicians other than rheumatologists for the management of rheumatology diseases and their comorbidities.</p> <p>Indeed, rheumatology is a multidisciplinary branch of medicine concerned with the study of a wide range of disorders that affect joints, muscles, bones, connective tissues, skin, eyes and systemic inflammatory conditions and that can have a significant impact on healthcare systems, being one of the most common causes of disability and work-related absences. In addition, patients with rheumatologic diseases have been found to be at increased risk of developing a variety of comorbid conditions like malignancies, cardiovascular disease, infections, kidney, lung and gastrointestinal diseases, and depression.</p> <p>Therefore, <strong>Beyond Rheumatology</strong> is addressed to a wide array of physicians, rheumatologists, immunologists, orthopedics, endocrinologists, rehabilitation doctor, dermatologist, radiologists, and other clinical specialists working directly for the management of rheumatology diseases and their comorbidities.</p> http://www.beyond-rheumatology.org/index.php/br/article/view/7 Transthoracic ultrasound versus intraoperative ultrasound in patients with pulmonary fibrosis: Reappraisal of artifacts 2019-09-04T12:14:11+02:00 Marco Sperandeo sperandeom@libero.it Giulia Gaudiuso gaudiuso.giulia@gmail.com Carla Maria Irene Quarato c.quarato@libero.it Anna Del Colle annadelcolle@gmail.com Michele Inglese m.inglese@operapadrepio.it Francesca Molinaro f.molinaro@operapadrepio.it Salvatore De Cosmo s.decosmo@operapadrepio.it Lucia Dimitri lmcdimitri@libero.it Marco Bizzarri m.bizzarri@operapadrepio.it Elisabettamaria Frongillo elisabettamaria.frongillo@gmail.com <p>In the last years, transthoracic ultrasound (TUS) has regained a growing interest from both clinicians and radiologists as a useful and non-invasive diagnostic tool for the study of many pleuropulmonary conditions, including interstitial lung diseases. Intraoperative lung ultrasound (ILU) is an ultrasound technique, developed for lung surface assessment during video-assisted thoracoscopic surgery procedures. It has been developed considering ultrasound basic physical principles for images generation and interpretation. Most of the TUS findings are due to the high difference in acoustic impedance between the chest-wall structures and the air in the lungs. In this brief communication, we compared ILU and TUS images in interstitial lung diseases. Most of the TUS artifacts-based diagnostic algorithms should be reappraised.</p> 2019-05-06T17:39:49+02:00 Copyright (c) 2019 Marco Sperandeo, Giulia Gaudiuso, Carla Maria Irene Quarato, Anna Del Colle, Michele Inglese, Francesca Molinaro, Salvatore De Cosmo, Lucia Dimitri, Marco Bizzarri, Elisabettamaria Frongillo http://www.beyond-rheumatology.org/index.php/br/article/view/4 The journey of canakinumab; on- and off-label indications 2019-09-04T12:13:55+02:00 Daniela Marotto piercarlo.sarziputtini@gmail.com Alberto Batticciotto piercarlo.sarziputtini@gmail.com Angela Ceribelli piercarlo.sarziputtini@gmail.com Piercarlo Sarzi Puttini piercarlo.sarziputtini@gmail.com <p>The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarize the on- and off-label use of canakinumab (ILARIS®).</p> 2019-05-06T17:39:26+02:00 Copyright (c) 2019 Daniela Marotto, Alberto Batticciotto, Angela Ceribelli, Piercarlo Sarzi Puttini